Literature DB >> 30250934

SETD2 in MLL-rearranged leukemia - a complex case.

Anna Skucha1,2, Jessica Ebner2, Florian Grebien2,3.   

Abstract

Oncogenic MLL-fusion proteins often hijack essential molecular mechanisms during leukemogenesis. The histone methyltransferase SETD2 was implicated in the regulation of transcription, DNA damage and other cellular processes. Recent studies identified a critical role for SETD2 in MLL-rearranged leukemia. These results may help to unravel important functions of SETD2 in hematopoiesis.

Entities:  

Keywords:  AML; MLL-rearranged leukemia; SETD2; fusion proteins

Year:  2018        PMID： 30250934      PMCID： PMC6150042          DOI： 10.1080/23723556.2018.1503492

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  The emerging complexity of gene fusions in cancer.

Authors:  Fredrik Mertens; Bertil Johansson; Thoas Fioretos; Felix Mitelman
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

2.  Identification of functional cooperative mutations of SETD2 in human acute leukemia.

Authors:  Xiaofan Zhu; Fuhong He; Huimin Zeng; Shaoping Ling; Aili Chen; Yaqin Wang; Xiaomei Yan; Wei Wei; Yakun Pang; Hui Cheng; Chunlan Hua; Yue Zhang; Xuejing Yang; Xin Lu; Lihua Cao; Lingtong Hao; Lili Dong; Wei Zou; Jun Wu; Xia Li; Si Zheng; Jin Yan; Jing Zhou; Lixia Zhang; Shuangli Mi; Xiaojuan Wang; Li Zhang; Yao Zou; Yumei Chen; Zhe Geng; Jianmin Wang; Jianfeng Zhou; Xin Liu; Jianxiang Wang; Weiping Yuan; Gang Huang; Tao Cheng; Qian-Fei Wang
Journal:  Nat Genet       Date:  2014-02-09       Impact factor: 38.330

Review 3.  The molecular mechanics of mixed lineage leukemia.

Authors:  R K Slany
Journal:  Oncogene       Date:  2016-02-29       Impact factor: 9.867

Review 4.  Shaping the cellular landscape with Set2/SETD2 methylation.

Authors:  Stephen L McDaniel; Brian D Strahl
Journal:  Cell Mol Life Sci       Date:  2017-04-06       Impact factor: 9.261

5.  SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.

Authors:  Brenton G Mar; S Haihua Chu; Josephine D Kahn; Andrei V Krivtsov; Richard Koche; Cecilia A Castellano; Jacob L Kotlier; Rebecca L Zon; Marie E McConkey; Jonathan Chabon; Ryan Chappell; Peter V Grauman; James J Hsieh; Scott A Armstrong; Benjamin L Ebert
Journal:  Blood       Date:  2017-10-10       Impact factor: 22.113

6.  Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains.

Authors:  Junwei Shi; Eric Wang; Joseph P Milazzo; Zihua Wang; Justin B Kinney; Christopher R Vakoc
Journal:  Nat Biotechnol       Date:  2015-05-11       Impact factor: 54.908

7.  The MLL recombinome of acute leukemias in 2017.

Authors:  C Meyer; T Burmeister; D Gröger; G Tsaur; L Fechina; A Renneville; R Sutton; N C Venn; M Emerenciano; M S Pombo-de-Oliveira; C Barbieri Blunck; B Almeida Lopes; J Zuna; J Trka; P Ballerini; H Lapillonne; M De Braekeleer; G Cazzaniga; L Corral Abascal; V H J van der Velden; E Delabesse; T S Park; S H Oh; M L M Silva; T Lund-Aho; V Juvonen; A S Moore; O Heidenreich; J Vormoor; E Zerkalenkova; Y Olshanskaya; C Bueno; P Menendez; A Teigler-Schlegel; U Zur Stadt; J Lentes; G Göhring; A Kustanovich; O Aleinikova; B W Schäfer; S Kubetzko; H O Madsen; B Gruhn; X Duarte; P Gameiro; E Lippert; A Bidet; J M Cayuela; E Clappier; C N Alonso; C M Zwaan; M M van den Heuvel-Eibrink; S Izraeli; L Trakhtenbrot; P Archer; J Hancock; A Möricke; J Alten; M Schrappe; M Stanulla; S Strehl; A Attarbaschi; M Dworzak; O A Haas; R Panzer-Grümayer; L Sedék; T Szczepański; A Caye; L Suarez; H Cavé; R Marschalek
Journal:  Leukemia       Date:  2017-07-13       Impact factor: 11.528

8.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.

Authors:  Gillian L Dalgliesh; Kyle Furge; Chris Greenman; Lina Chen; Graham Bignell; Adam Butler; Helen Davies; Sarah Edkins; Claire Hardy; Calli Latimer; Jon Teague; Jenny Andrews; Syd Barthorpe; Dave Beare; Gemma Buck; Peter J Campbell; Simon Forbes; Mingming Jia; David Jones; Henry Knott; Chai Yin Kok; King Wai Lau; Catherine Leroy; Meng-Lay Lin; David J McBride; Mark Maddison; Simon Maguire; Kirsten McLay; Andrew Menzies; Tatiana Mironenko; Lee Mulderrig; Laura Mudie; Sarah O'Meara; Erin Pleasance; Arjunan Rajasingham; Rebecca Shepherd; Raffaella Smith; Lucy Stebbings; Philip Stephens; Gurpreet Tang; Patrick S Tarpey; Kelly Turrell; Karl J Dykema; Sok Kean Khoo; David Petillo; Bill Wondergem; John Anema; Richard J Kahnoski; Bin Tean Teh; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2010-01-06       Impact factor: 49.962

9.  Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.

Authors:  Brenton G Mar; Lars B Bullinger; Kathleen M McLean; Peter V Grauman; Marian H Harris; Kristen Stevenson; Donna S Neuberg; Amit U Sinha; Stephen E Sallan; Lewis B Silverman; Andrew L Kung; Luca Lo Nigro; Benjamin L Ebert; Scott A Armstrong
Journal:  Nat Commun       Date:  2014-03-24       Impact factor: 14.919

10.  MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity.

Authors:  Anna Skucha; Jessica Ebner; Johannes Schmöllerl; Mareike Roth; Thomas Eder; Adrián César-Razquin; Alexey Stukalov; Sarah Vittori; Matthias Muhar; Bin Lu; Martin Aichinger; Julian Jude; André C Müller; Balázs Győrffy; Christopher R Vakoc; Peter Valent; Keiryn L Bennett; Johannes Zuber; Giulio Superti-Furga; Florian Grebien
Journal:  Nat Commun       Date:  2018-05-18       Impact factor: 17.694
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.